Research in movement disorders in 2022: a new era of biomarker and treatment development

Lancet Neurol. 2023 Jan;22(1):17-19. doi: 10.1016/S1474-4422(22)00494-X.

Authors

Christine Klein¹, Bastiaan R Bloem²

Affiliations

¹ Institute of Neurogenetics, University of Lübeck, Lübeck, 23538, Germany. Electronic address: christine.klein@neuro.uni-luebeck.de.
² Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Centre of Expertise for Parkinson & Movement Disorders, Nijmegen, the Netherlands.

PMID: 36517158
DOI: 10.1016/S1474-4422(22)00494-X

No abstract available

MeSH terms

Biomarkers
Humans
Movement Disorders* / diagnosis
Movement Disorders* / therapy

Substances

Biomarkers